Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Inclusion Criteria:

Diagnosis of HD with documented CAG repeat ≥ 37
UHDRS total maximal chorea score of ≥ 8
Able to walk at least 10 meters
Medically stable outpatient, based on the investigator's judgment
Willing and able to give written informed consent prior to performing any study procedures
Have completed at least 10th grade
Montreal Cognitive Assessment score ≥ 22 on screening
Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion

Exclusion Criteria:

Severe depression or suicidal ideation
History of suicidal behavior
Unstable or serious medical or psychiatric illness
Renal or hepatic impairment
Severe speech impairment or anarthria
Inability to swallow study medication
Women who are pregnant or breast feeding
History of alcohol or substance abuse within the last 12 months
Current use of VMAT2 inhibitor (tetrabenazine, deutetrabenazine, valbenazine)
Concurrent participation in any other investigational drug trials
EKG QTcF> 500 mse